BridgeBio Pharma, Inc. 8-K

What Happened

• BridgeBio Pharma, Inc. filed a registration statement on Form S-3ASR and on May 7, 2026 entered an Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC to sell, at its option, up to $500,000,000 of common stock through an at-the-market (ATM) program. Sales may occur on Nasdaq or other trading markets and the Sales Agents will use commercially reasonable, best-efforts practices to sell shares per the company’s instructions. The company filed the 8-K on May 8, 2026.
• In connection with the new agreement, BridgeBio terminated its prior Equity Distribution Agreement dated May 4, 2023, effective May 7, 2026.

Key Details

• Registration Statement: Form S-3ASR filed May 7, 2026 (File No. 333-295678).
• Offering capacity: up to $500,000,000 aggregate offering price of common stock via an ATM program.
• Sales agents: Goldman Sachs & Co. LLC and Leerink Partners LLC; commission up to 3.0% of gross proceeds.
• Prior agreement dated May 4, 2023 was terminated effective May 7, 2026.

Why It Matters

• This ATM program gives BridgeBio flexible, market-priced access to raise up to $500M of equity capital over time, which can be used to support operations, R&D and other corporate needs.
• The company is not obligated to sell shares (and the agents are not required to sell any set amount), so actual dilution depends on future decisions and market conditions. Commissions (up to 3%) and any future issuances will affect net proceeds and share count.
• Investors should watch for prospectus supplements and future sales notices to see if and when BridgeBio actually issues shares under this program.